Navigation Links
Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
Date:8/21/2007

CHICAGO, Aug. 21 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced the commencement of its collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the lead governmental institute supporting biodefense research, under which the NIAID will conduct studies to evaluate cethromycin, the Company's late-stage antibiotic, as a treatment for anthrax and other high-priority biodefense agents. This collaboration is part of the U.S. Government's effort to accelerate the research and development of medical countermeasures through the crucial phase of drug development between basic research and acquisition of final products under Project BioShield.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO)

Project BioShield provides the Department of Health and Human Services with the authority and funding to procure promising countermeasures for addition to the Strategic National Stockpile, which is the Center for Disease Control and Prevention's store of medical supplies to protect the American public in the event of a public health emergency. Project BioShield provides the NIAID, part of the National Institutes of Health, with the authority to support development of countermeasures toward possible future procurement with Project BioShield funds.

"We are very excited about our partnership with the NIAID as it allows us to leverage the financial and scientific resources of the U.S. Government's premier research institute to develop cethromycin as a broad spectrum medical countermeasure," said Dr. Michael T. Flavin, Chief Executive Officer. "With the threat of growing resistance to currently available therapies, the U.S. Government is focused on procuring next-generation products with a broad spectrum of activity to complement currently-held medical countermeasures in the Strategic National Stockpile. This partnership with NIAID will expand the data on cethromycin as a biodefense application, and we expect the results to strengthen our efforts in positioning cethromycin for purchase by the U.S. Government."

In May, Advanced Life Sciences announced positive data from a study that showed cethromycin to be effective in preventing inhalation anthrax infection in primates. The study, involving a 30-day course of oral dosing, demonstrated that cethromycin was 100% protective against a lethal dose of inhaled anthrax as compared to the current standard of care, Cipro(R) (ciprofloxacin), which demonstrated 90% protection. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post-exposure, however the FDA has not yet approved the drug for marketing in this or any other indication.

About Project BioShield

The Project BioShield Act of 2004 (Public Law 108-276) is aimed at accelerating the research and development of medical countermeasures by instituting a secure funding source ($5.6 Billion over 10 years) for the purchase of critical medical countermeasures, such as vaccines, therapeutics and diagnostics. Project BioShield also grants the NIAID authority to expedite and simplify the solicitation, review, and award of grants and contracts for the development of critical medical countermeasures. Finally, Project BioShield establishes the Emergency Use Authorization (EUA) to provide access to the best available medical countermeasures following a Declaration of Emergency by the Secretary of Health and Human Services.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including community acquired pneumonia (CAP). For more information, please visit us on the web at http://www.advancedlifesciences.com.

About Cethromycin

Advanced Life Sciences is developing cethromycin, a novel once-a-day antibiotic in response to the emerging bacterial resistance observed in the treatment of CAP. In addition to its utility in CAP, cethromycin was also recently shown to be effective in preventing inhalation anthrax (Bacillus anthracis) infection post-exposure in a primate study. Cethromycin has been tested in approximately 5,000 human subjects during clinical trials. The Company believes that cethromycin, if approved, would build upon the growing market opportunity in the antibiotic marketplace and address the critical need for antibiotics that overcome bacterial resistance.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Except for historical information, the statements made in this press release are forward-looking statements about Advanced Life Sciences Holdings, Inc., including statements regarding the clinical trials and regulatory pathway of cethromycin. Forward-looking statements represent our management's judgment regarding future events and are accurate at the time they are made. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, capital requirements, and our ability to access capital through partnerships, stock offerings and future revenues; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
10. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... COUNTY, Calif. , Oct. 10, 2017  NDS received FDA ... Mobile  — a medical-grade battery-powered display stand specifically designed for endoscopy ... to transform technology into a clinical solution to support the improvement ... Innovative Design ... ZeroWire Mobile Wireless Solution ...
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... 2017 , ... In the United States, single-family home owners ... New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 ... property-tax rates, which contributes to the relatively lower cost of living in places ...
Breaking Medicine News(10 mins):